Press release Biocartis Group NV: BIOCARTIS MEETS 2021 KEY OBJECTIVES

by NASDAQ Market News January 10, 2022

NASDAQ Market News
Click here to email author

Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19

Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia

Ads